Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00004151 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2012-09-24
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have advanced non-small cell lung cancer that cannot be treated with surgery.
Conditions
Interventions
- DRUG
-
acridine carboxamide
Sponsors & Collaborators
-
European Organisation for Research and Treatment of Cancer - EORTC
lead NETWORK
Principal Investigators
-
Axel R. Hanauske, MD, PhD, MBA · Haemato-Onkologische Praxis und Tagesklinik
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-09-30
- Primary Completion
- 2000-11-30
Countries
- Austria
- Denmark
- France
- Germany
- Italy
- Spain
Study Locations
More Related Trials
-
KRN7000 in Treating Patients With Solid Tumors
NCT00003985 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
NCT04972981 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
NCT00422097 ·Status: COMPLETED ·Phase: PHASE1
-
Decitabine in Treating Patients With Advanced Solid Tumors
NCT00030615 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
NCT03700294 ·Status: TERMINATED ·Phase: PHASE1
-
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors
NCT01300468 ·Status: COMPLETED ·Phase: PHASE1
-
XK469 in Treating Patients With Advanced Solid Tumors
NCT00028548 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
NCT07151040 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
NCT03261011 ·Status: COMPLETED ·Phase: PHASE1
-
Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05474859 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
IACS-010759 in Advanced Cancers
NCT03291938 ·Status: COMPLETED ·Phase: PHASE1
-
AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma
NCT00390117 ·Status: COMPLETED ·Phase: PHASE1
-
Study of AS1411 in Advanced Solid Tumours
NCT00881244 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06630247 ·Status: TERMINATED ·Phase: PHASE1
-
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
NCT00243347 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
NCT03530397 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT04250155 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
NCT03421353 ·Status: COMPLETED ·Phase: PHASE1
-
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer
NCT04630756 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
NCT06667141 ·Status: RECRUITING ·Phase: PHASE1
-
Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors
NCT07110584 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
SB-743921 In Patients With Solid Tumors
NCT00136513 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
NCT03352531 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors
NCT00724100 ·Status: TERMINATED ·Phase: PHASE1